Nalmefene

Nalmefene

SCHEMBL12646154

C=C1CC[C@]2(O)[C@@H]3Cc4ccc(O)c5c4[C@]2(CCN3CC2CC2)C1O5

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRD1OPRK1OPRM1

The experimentally established mechanism targets of Nalmefene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRD1 known ✓ P41143 12/20 1.00
OPRM1 known ✓ P35372 10/20 1.00
OPRK1 known ✓ P41145 9/20 1.00
NR1I2 O75469 1/20 1.00
KCNH2 Q12809 1/20 1.00
CYP2D6 P10635 3/20 0.80
CYP1A2 P05177 2/20 0.80
CHRNA7 P36544 1/20 0.80
PKM P14618 1/20 0.80
SMN1; SMN2 Q16637 1/20 0.78
LMNA P02545 1/20 0.77
HIF1A Q16665 1/20 0.77
MAPT P10636 2/20 0.70
KDM4E B2RXH2 2/20 0.70
USP2 O75604 1/20 0.70
CYP3A4 P08684 1/20 0.70
TSHR P16473 1/20 0.70
HSD17B10 Q99714 1/20 0.70
MAPK8 P45983 1/20 0.70
MAPK9 P45984 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nalmefene SCHEMBL14124638 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2
Nalmefene SCHEMBL4556466 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2
Nalmefene SCHEMBL18827079 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2
Nalmefene SCHEMBL18457569 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2
Nalmefene SCHEMBL35230 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2
Nalmefene SCHEMBL18160036 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2
Nalmefene SCHEMBL12945213 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2
Nalmefene SCHEMBL17168341 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2
Nalmefene SCHEMBL12566030 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2
Nalmefene SCHEMBL12233286 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1NR1I2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170029432-A1 (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF MALLINCKRODT ENTERPRISES LLC 2017-02-02 US disclosed
US-20110136845-A1 (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof MALLINCKRODT INC. (US) 2011-06-09 US disclosed
US-20110015219-A1 (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof MALLINCKRODT INC. (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170029432-A1 (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF TLR9, TLR3, TLR7 OPRD1 13/4885OPRM1 5/4885OPRK1 11/4885
US-20110136845-A1 (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof TLR9, TLR3, TLR7 OPRD1 13/4885OPRM1 5/4885OPRK1 11/4885
US-20110015219-A1 (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof TLR9, TLR3, TLR1 OPRD1 51/4885OPRM1 17/4885OPRK1 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.